Provided by Tiger Fintech (Singapore) Pte. Ltd.

Catalyst Pharmaceuticals

21.01
-0.3500-1.64%
Post-market: 20.86-0.1500-0.71%17:50 EDT
Volume:1.01M
Turnover:21.34M
Market Cap:2.57B
PE:12.75
High:21.30
Open:21.16
Low:20.88
Close:21.36
52wk High:26.58
52wk Low:19.05
Shares:122.39M
Float Shares:115.02M
Volume Ratio:1.02
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.65
EPS(LYR):1.38
ROE:28.49%
ROA:18.13%
PB:3.00
PE(LYR):15.19

Loading ...

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 17

Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Sep 16

Catalyst Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Sep 13

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 12

Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Sep 09

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 06

Brian Elsbernd, Chief Compliance/Legal Officer, Reports Disposal of Common Shares in Catalyst Pharmaceuticals Inc

Reuters
·
Sep 06

Catalyst Pharmaceuticals Inc. Stock Falls 3.7%, Underperforms Peers

Dow Jones
·
Sep 04

Catalyst Pharmaceuticals President and CEO Richard J. Daly Reports Disposal of Common Shares

Reuters
·
Aug 29

Catalyst Pharmaceuticals Inc. to Participate in 2025 Wells Fargo Healthcare Conference

Reuters
·
Aug 28

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 28

Catalyst Pharmaceuticals Inc - and Lupin to Terminate Patent Litigation Between Catalyst/Serb and Lupin

THOMSON REUTERS
·
Aug 27

Catalyst Pharmaceuticals Inc - Lupin to Delay Generic Firdapse Launch Until Feb 25, 2035

THOMSON REUTERS
·
Aug 27

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

GlobeNewswire
·
Aug 27

Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Aug 26

Catalyst Pharmaceuticals Settles Patent Litigation with Lupin, Grants License for Generic FIRDAPSE Marketing Starting February 2035

Reuters
·
Aug 25

Catalyst : Pending Firdapse Patent Litigation Against Remaining Defendant, Hetero, Regarding Firdapse's Orange Book-Listed Patents Is Ongoing

THOMSON REUTERS
·
Aug 25

Catalyst Pharmaceuticals Inc - Lupin to Delay Generic Firdapse Launch Until 2035

THOMSON REUTERS
·
Aug 25

Catalyst Pharmaceuticals Announces Settlement of Firdapse® (Amifampridine) Patent Litigation With Lupin Pharmaceuticals

THOMSON REUTERS
·
Aug 25

Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 22